Baijin Life Science Unit, Foryoung Tie Up for Clinical Cell Therapy Business
Baijin Life Science (HKG:1466) unit Beijing Baijin Biotechnology entered into an agreement with Foryoung Biotechnology for strategic cooperation, according to a Wednesday filing with the Hong Kong bourse.The parties will cooperate in the clinical cell therapy niche.Beijing Baijin Biotechnology will be responsible for the R&D, production, quality control, and global supply chain support of various products, with Foryoung Biotechnology integrating its technological capabilities in the process.